tiprankstipranks
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Hong Kong Market

Wuxi Biologics (Cayman) (2269) Income Statement

Compare
37 Followers

Wuxi Biologics (Cayman) Income Statement

Last quarter (Q2 2024), Wuxi Biologics (Cayman)'s total revenue was ¥8.57B, an increase of 101.94% from the same quarter last year. In Q2, Wuxi Biologics (Cayman)'s net income was ¥1.50B. See Wuxi Biologics (Cayman)’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
¥ 17.03B¥ 15.27B¥ 10.29B¥ 5.61B¥ 3.98B
Gross Profit
¥ 6.83B¥ 6.72B¥ 4.83B¥ 2.53B¥ 1.66B
Operating Expenses
¥ 2.88B¥ 1.93B¥ 1.36B¥ 771.43M¥ 601.77M
Depreciation and Amortization
¥ 1.17B¥ 800.67M¥ 481.78M¥ 303.01M¥ 221.37M
EBITDA
¥ 5.50B¥ 6.22B¥ 4.51B¥ 2.31B¥ 1.37B
Operating Income
¥ 3.95B¥ 6.16B¥ 3.86B¥ 1.76B¥ 1.11B
Other Income/Expenses
¥ 224.34M¥ 1.02B¥ 805.01M¥ 463.73M¥ 69.57M
Pretax Income
¥ 4.17B¥ 5.36B¥ 3.99B¥ 1.97B¥ 1.13B
Net Income
¥ 3.40B¥ 4.42B¥ 3.39B¥ 1.69B¥ 1.01B
Per Share Metrics
¥ ―¥ ―¥ ―¥ ―¥ ―
Basic EPS
¥ 0.77¥ 1.06¥ 0.81¥ 0.43¥ 0.27
Diluted EPS
¥ 0.78¥ 1.01¥ 0.77¥ 0.40¥ 0.25
Weighted Average Shares Outstanding
4.40B 4.17B 4.40B 4.21B 4.00B
Weighted Average Shares Outstanding (Diluted)
4.35B 4.38B 4.42B 4.21B 4.00B
Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis